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Dissertation abstract 
Javanmardi, N., 2017, Genomic instability and genetic heterogeneity in neuroblastoma 
Department of Pathology and Clinical Genetics, Institute of Biomedicine at 
Sahlgrenska Academy, University of Gothenburg, Sweden 
 
Neuroblastoma (NB), a tumour of the sympathetic nervous system and the most 
common malignant disease of early childhood, is responsible for 9% of paediatric 
cancer related deaths. Aggressive NB still constitutes a major clinical problem 
with survival rates of about 35%. It is therefore of great clinical interest to further 
study the biological parameters that can (i) better classify tumours so that the 
children may be given the right treatment (ii) identify new actionable targets. 
Aim - the objective of this thesis was to explore genes and chromosomal regions 
with potential involvement in the initiation/progression of NB that can be used 
for improved patient stratification. 
Results – In paper I and III we detected point mutations in the tyrosine kinase 
domain of the ALK oncogene. Minor population of cells with ALK mutations 
were detected with massive parallel deep DNA sequencing. It is likely that early 
detection of subclones with ALK mutation is critical in treatment of these 
tumours with recently derived small molecule ALK inhibitors. We propose 
increased serial sampling of tumour material from high-risk NB tumours and 
analysis with the new sequencing techniques.  
In paper II we observed that the distal part of chromosome arm 2p often is 
subjected to gain of an extra copy – i.e. 2p-gain. Interestingly, this region contains 
three genes, ALKAL2, MYCN and ALK, of strong importance for NB 
development. We suggest that the gain of this “cassette” of genes is beneficial to 
the NB tumor pathogenesis with potential to aid in therapeutical intervention.  
In the last study, paper IV, we analysed the high-risk 11q-deleted NB tumours. 
We show that 11q-deleted tumours with and without MYCN amplification 
present different 11q-deletion breakpoint patterns. The detailed analysis of these 
patterns enabled us to detect genes and chromosomal regions on 11q that may 
contain tumour suppressors in this severe child cancer subgroup. Furthermore, 
we propose DLG2 as a highly interesting 11q candidate NB gene.  
Conclusion - Our observation of a significant spatiotemporal variation of ALK 
mutations is of utmost importance in clinical practice. DLG2 stands out as a 
strong tumor suppressor candidate for the 11q-deleted NBs. It is important to 
note that the experiments we propose are expected to contribute to precision 
medicine. 
Keywords - tumour, neural crest, neuroblastoma, subclone, mutation, relapse, 
deep sequencing, microarray, 2p, MYCK, ALK, ALKAL2, 11q, DLG2, CCND1 
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Neuroblastom (NB) är en barncancerform där tumörer uppkommer i det sympatiska 
nervsystemet. NB är en av de vanligaste tumörformerna bland unga barn och orsakar 
9 % av alla cancerrelaterade dödsfall hos barn. Den mest aggressiva formen av NB är 
mycket svårbehandlad och överlevnaden för denna grupp endast är cirka 35 %. Därför 
är det av stor betydelse att studera biologiska faktorer som kan (i) användas för att 
förbättra klassificeringen av tumörer så att barnen får rätt behandling (ii) identifiera 
nya möjliga behandlingsmål. 
 
Syfte – Syftet med denna avhandling är att utforska förändringar i gener och 
kromosomala regioner som kan vara involverade i uppkomst/progression av NB och 
som kan användas till förbättrad patientgruppering inför behandling. 
 
Resultat – I arbete I och III studerade vi förekomsten av aktiverande 
punktmutationer i kinasdomänen hos onkogenen ALK. Genom att använda ultradjup 
DNA-sekvensering kunde vi påvisa närvaro av förändringar i ALK som bara förekom 
i en liten andel av cellerna i tumören. Då ett flertal läkemedel som inhiberar ALK är 
under utveckling så tror vi att möjligheten att detektion av subklonala ALK-
mutationer är av stor betydelse för NB-patienter. För att kunna fånga upp 
mutationerna i så tidigt skede som möjligt så föreslår vi en mer frekvent provtagning 
av högrisk-NB och analys med den nya DNA-sekvenseringsteknologin. 
 
I arbete II observerar vi att den distala delen av det kromosomala området 2p ofta 
förekommer i en extra kopia, ett så kallat 2p-gain. Intressant nog så ligger tre gener; 
ALKAL2, MYCN och ALK, som alla har stor betydelse för utveckling av NB inom 
denna region. Vi tror att extrakopior av dessa tre gener tillsammans har en drivande 
funktion vid uppkomsten av NB och därför kan vara viktigt att ta i beaktande vid val 
av behandlingsstrategi. 
 
I arbete IV studerade vi gruppen av hög-risk NB med 11q-deletion. Vi visar att 
tumörer med 11q-deletion har olika mönster av brottspunkter på 11q beroende av om 
tumörerna också har amplifiering av MYCN. Detaljerad analys av brottspunkter och 
deletioner gör det möjligt att identifiera genomiska områden inom 11q som kan 
innehålla tumörsuppressorgener i denna aggressiva grupp av NB-tumörer. En mycket 
intressant kandidat-tumörsuppressorgen som identifierats inom det frekvent 
deleterade området på 11q är DLG2. 
 
Slutsats – I våra studier observerar vi skillnader i förekomst av ALK-
mutationer, både inom tumören och över tid, vilket kan vara av yttersta vikt i 
den kliniska utvärderingen. Det påvisar vikten av att använda ultrakänsliga 
metoder som t.ex. den nya DNA-sekvenseringsteknologin men också behovet 
av ökad provtagningsfrekvens. Vi visar också att DLG2 utmärker sig som en 
stark tumörsuppressorkandidat för gruppen av NB-tumörer med 11q-
deletion. Det är också viktigt att notera att de analyser som vi föreslår är ett 
led till individanpassad behandling, dvd att ge rätt behandling till rätt patient. 
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INTRODUCTION 
BASIC GENETICS 
DNA and genes 
In human cell nuclei, the genetic information is stored into two sets of 23 DNA 
molecules called chromosomes, half of which are inherited from the mother and 
half from the father. In eukaryotes, DNA is found in the nucleus, in the 
mitochondria and also in chloroplast of plants. A DNA molecule consists of two 
twisted complementary paired strands, called helix, as described by Watson and 
Crick in 1953 (Watson & Crick 1953). Each strand is built up by four different 
nucleotides bases, adenine (A), cytosine (C), guanine (G) and thymine (T). Each 
nucleotide in one chain is specifically linked to a nucleotide in other chain referred 
to as base pairs (bp), an A always pair with a T and a C with a G. The usage of 
different combinations of these bases makes the genetic code. 
 
 
Figure  1 A human female karyotype showing 46 chromosomes, 23 chromosome pairs. 
The human genome contains approximately 3.2 billion nucleotides and about 
19,000 protein coding genes (Ezkurdia et al 2014). Each gene is comprised of the 
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protein coding segments, known as exons; the intervening non-coding sequences, 
known as introns; and the regulatory regions on each end of the gene (5’ and 3’ end 
regions). The first and the last exon commonly also include untranslated regions 
(UTRs), which is important for RNA stability and translation. There are about 
180,000 exons in each human genome that are collectively referred to as an exome. 
An exome comprises about 1% of the human genome and hence, is about 30 
million nucleotides in size. 
The central dogma of molecular biology 
The flow of genetic information from DNA to RNA to polypeptide has been 
described as the central dogma (Crick 1958). During transcription, the RNA-
polymerase transcribes the DNA gene sequence to a newly synthesized pre-mRNA 
(messenger RNA). The pre-mRNA is processed to a mature RNA through excision 
of introns, addition of a 5′ methylated nucleoside as protective cap and 
polyadenylation at the 3′ end. Following post-transcriptional modification, the 
mRNA is released from the DNA and will be transported out from the nucleus to 
the cytoplasm to be used as a blueprint for the protein to be produced. After 
migration to the cytoplasm, the mRNA is translated into polypeptides at the 
ribosome (a multiunit RNA-protein complex). The connection between mRNA and 
protein is made through a set of transfer RNAs (tRNAs), each containing a three 
nucleotides long recognition sequence. To become a fully functional protein the 
amino acid chain folds up into a unique three-dimensional configuration and 
possibly undergoes post-translational modification. 
 
Figure  2.  The central dogma of molecular biology. 
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Genetic variations 
A single nucleotide polymorphism (SNP), 3.5×106 abundance in the human 
genome, is a common variation in the DNA sequence in which one nucleotide at 
the specific locus differs between individuals. Usually, a SNP has two alleles, 
although three and four allele SNPs exist, but they are rare. There is also a form of 
large scale polymorphism that involves DNA copy number variants (CNVs), 
defined as stretches of DNA larger than 1 kb that display copy number differences 
in the normal population (Scherer et al 2007). Change of copy number is implicated 
to be important in functional diversity and individual CNVs have shown to be 
associated with disease or susceptibility to disease (de Smith et al 2008). 
Polymorphism definition refers to a DNA sequence variation that occur naturally in 
population and are not disease causing. However, the term “mutation” is more 
commonly used for pathogenic alteration in DNA. Mutations result from 
unrepaired damage to DNA, errors in the process of replication, or from the 
insertion or deletion of segments of DNA by mobile genetic elements. Mutations 
are often found in coding regions of the gene, but could also be found in regulatory 
elements and other locations that could have implications in both normal and 
abnormal biological processes including evolution, cancer, and the development of 
the immune system. The sequence of a gene can be altered in a number of ways. 
Point mutations, exchange of a single nucleotide for another, which results in an 
amino acid variation, is called nonsynonymous, and one that does not is called 
synonymous. Nonsynonymous mutations can be further divided into missense and 
nonsense variations. A missense variation results in a different amino acid and a 
nonsense variation results in a premature stop codon that causes a truncated 
protein. In addition to basepair substitution, mutations can also result from 
deletions or insertions in the coding region of a gene, which may alter splicing of 
the mRNA (splice site mutation), or cause a shift in the open reading frame if the 
number of the involved nucleotides is not a multiple of three (frameshift mutation). 
Cancer cells often exhibit large-scale chromosomal abnormalities, including 
deletions, amplifications, translocations (interchange of genetic parts from 
nonhomologous chromosomes) and inversion. 
Organization of the genetic material 
Each human cell has about 2 meters of DNA, which is organized by the core-
packing unit of chromosome called nucleosome. The nucleosomes core particle 
consists of approximately 147 base pairs of DNA coiled around a histone octamer 
(two each of H2A, H2B, H3, and H4). The adjacent nucleosomes are connected by 
stretches of "linker DNA", viewed as “beads on a string” in an electron 
microscope. This “beads on a string” is compacted into a chromatin fibre that is 
condensed into long loops. Further compaction leads to transcriptionally inactive 
heterochromatin that can be visualized as chromosomes in light microscope during 
cell division. Between divisions, nucleosomes are relatively loosely packaged 
allowing expression of genetic information. 
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Figure  3 The organization of DNA within the chromatin structure. Reprinted with permission from 
Macmillan Publishers Ltd: Nature (Felsenfeld &Groudine, 2003), © 2003 
EPIGENETICS 
Epigenetic term refers to the cellular and physiological heritable traits that are 
caused by mechanisms other than changes in underlying DNA sequence, a change 
in phenotype without a change in genotype. Epigenetic is important for X 
chromosome inactivation in female mammals and is also responsible for 
chromosome imprinting. At least three systems, including DNA methylation, 
histone modification and non-coding RNA (ncRNA)-associated gene silencing are 
currently considered to initiate and sustain epigenetic change (Egger et al 2004). 
DNA methylation 
DNA methylation is one of the most well characterized epigenetic modifications 
dating back to studies done by Griffith and Mahler in 1969 which suggested that 
DNA methylation may be important in long term memory function (Griffith & 
Mahler 1969; Holliday 2006). During methylation, DNA methyltransferases 
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(DNMTs) enzyme adds a methyl group to cytosine in CpG dinucleotides (cytosine - 
guanine dinucleotides). The majorities of CpG sites are located within repetitive 
elements and are methylated. Another place where they are found is in CpG islands 
associates with the promoter of genes, normally unmethylated (Esteller 2002). 
Adding methyl groups modifies a gene's interactions with the machinery within a 
cell's nucleus that is needed for transcription and is associated with gene silencing. 
Histone Modifications 
When histones are modified after they are translated into protein, i.e. post-
translation modification, they can influence how chromatin is arranged, which in 
turn can determine whether the associated chromosomal DNA will be transcribed. 
Histones can be modified in different ways including methylation, acetylation, 
phosphorylation, and ubiquitination. Acetylation is usually associated with active 
chromatin, while deacetylation is generally associated with heterochromatin. It has 
been proposed that the combination of modifications constitute a so called 
“histone code” which defines the status of the chromatin structure (Jenuwein & 
Allis 2001). 
RNA-associated silencing 
Small, non-coding RNAs that bind to target mRNAs transcripts in a sequence-
specific manner can also turn off genes activity. The main classes of small RNA are 
short interfering RNAs (siRNA), microRNAs (miRNA) and PIWI-interacting 
RNAs (piRNAs) (Jinek & Doudna 2009). The siRNA and miRNA origin from 
double-stranded RNA (dsRNA) and their generation depends on ribonuclease 
(RNase) Dicer. The siRNA has a double-stranded structure and the miRNA a 
single-stranded. Little is known about the piRNA, but they are generated from 
single-stranded RNA and have a function in silencing transposons in germ cells. 
Moreover, long non-coding RNAs (lncRNA) have recently emerged as gene 
regulators in several cancers. 
TAD regulation in the 3D genome 
Three-dimensional organization of the genome occurs coincident with genetic and 
epigenetic alterations. Structural boundaries between regions of chromatin define 
loops called topologically associated domains (TADs), within which gene activity is 
coordinated (Dixon et al 2012). TADs are conserved during evolution and play 
roles in controlling long-range chromatin interactions. They have contributed to the 
increment of regulatory complexity by allowing promoters to be activated or 
inactivated with different sets of cis-regulatory elements. 
 16  INTRODUCTION	
 
CANCER 
Cancer is a genetic disease characterized by out-of-control cell growth. Cancer is 
the result of several somatically acquired mutations and occasionally also an 
inherited predisposition. Cancer is not one single disease, there are over a hundred 
different types of cancer. The progression and pathology varies between types of 
cancers and between individuals and fighting the disease has therefore proven to be 
very challenging. Sweden has about 50,000 new cases each year and approximately 
22,000 dies from cancer annually. 
Oncogenes and tumour suppressor genes 
Two major groups of genes are involved in tumourigenesis, oncogenes and tumour 
suppressor genes (TSG). Oncogenes are altered versions of normal proto-
oncogenes whose normal function promotes cell proliferation. The gain of function 
mutations in these genes result in an excessive or inappropriate activation. 
 
Tumour suppressor genes (TSG) are inhibiting uncontrolled cell growth and 
inactivation of TSGs is just as important as oncogene activation in cancer 
pathogenesis. TSGs can be divided into gatekeepers and caretakers (Kinzler & 
Vogelstein 1997). Gatekeepers are genes that directly regulate the growth of 
tumours by inhibiting proliferation or promoting apoptosis. Both the maternal and 
paternal copy of the gene need to be altered for a tumour to develop and the 
inactivation of the gatekeepers is therefore rate limiting for the initiation of a 
tumour. The inactivation of a caretaker gene does not promote tumour initiation 
directly but leads to increased genetic instability that in turn leads to mutations of 
other genes. 
The two-hit hypothesis 
Knudson’s two-hit hypothesis states that two hits are needed for a TSG to be 
inactivated, exemplified by a childhood eye tumour, retinoblastoma (Knudson 
1971). The first hit can be a de novo mutation as in sporadic cancers or germline as 
in familiar cancer syndromes. The second hit can constitute of a second mutation, 
but more often a deletion of the remaining allele or promoter hypermethylation that 
silences this allele (Jones & Laird 1999), see Figure 4. The two-hit hypothesis is 
however not universal and there is evidence that haploinsufficiency, inactivation of 
one allele, can contribute to the tumourigenic process. 
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Figure  4.  Mechanisms of TSG inactivation in induction of cancer. (A) The first hit is a mutation affecting function of 
TSG. (B) The first hit is DNA hypermethylation which silences the gene. The second hit commonly constitutes somatic cell 
mutation, heterozygote loss, and DNA hypermethylation.  
Epigenetic and cancer 
Cancer was the first human disease to be linked to epigenetics (Feinberg & 
Vogelstein 1983). DNA hypomethylation can activate oncogenes and initiate 
chromosome instability, whereas DNA hypermethylation initiates silencing of 
tumour suppressor genes (Sakai et al 1991). An accumulation of genetic and 
epigenetic errors can transform a normal cell into an invasive or metastatic tumour 
cell. Subsequently, epigenetic changes can be used as biomarkers for the molecular 
diagnosis of early cancer. 
TAD and cancer 
Disruption of TAD boundaries, as recently detected in cancer cells, can lead to 
inappropriate promoter-enhancer communication and misregulation of oncogenes 
and tumour suppressors (Flavahan et al 2016; Valton & Dekker 2016). This 
alteration in the 3D folding of chromosomes contributes to oncogenesis through 
two mechanisms. One mechanism locally disrupts domains by mutating or 
epigenetically inactivating a TAD boundary. However, the other mechanism 
involves genomic rearrangements that break up TADs and creates new ones 
without directly affecting TAD boundaries. 
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NEUROBLASTOMA 
Epidemiology 
Neuroblastoma (NB) is the most frequent extracranial solid tumour in children, 
accounting for 7 to 8% of all childhood malignancies and 15% of all cancer-related 
deaths in this population. It is the most frequently diagnosed neoplasm during 
infancy (Brodeur 2003; Maris & Matthay 1999). The prevalence is about 1 in 7,000 
live births, with 15-20 new diagnosed cases a year in Sweden. The median age at 
diagnosis is approximately 18 months, 9 months in familial neuroblastoma. While 
90% of the patients are younger than 5 years, NB is very rare after the age of 10 
(Brodeur 2003). It is an embryonic tumour of the postganglionic sympathetic 
nervous system (SNS). Most NBs are composed of neuroblasts, undifferentiated 
sympathetic nerve cells arising from the neural crest. Tumours characterized by 
partial histological differentiation are called ganglioneuroblastoma (GNB) while the 
most differentiated tumour type is called ganglioneuroma (GN). Primary tumours 
are found in areas of the peripheral SNS, about half of all NBs arise in one of the 
adrenal glands, and the rest develop in paraspinal sympathetic ganglia in the chest, 
abdomen, or pelvis. Metastases often spread to regional lymph nodes, bone, bone 
marrow, and sometimes to the liver and skin in infants. NB is remarkable for its 
clinical heterogeneity. The clinical course can vary enormously ranging from 
spontaneous regression, particularly observed in infants, to inexorable progression 
and death despite multimodal treatments. Metastatic disease is present in 
approximately 50% of cases. 
Symptoms and treatment 
The symptoms of neuroblastoma are usually diffuse depending on the size and 
location of the primary tumour, the extent of spread to other parts of the body and 
whether or not the tumour cells secrete hormones. Weakness, fever, high blood 
pressure, pain, and weight loss are some of the symptoms while in some other 
patients it can remain asymptomatic. Due to the extreme heterogeneity in the 
clinical behaviour of this disease, a challenging task is not only to find a cure for the 
high-risk patients, but also to avoid overtreatment for the patients with a favourable 
prognosis. Surgical removal, chemotherapy, radiotherapy and biotherapy are among 
the treatment strategies for NB patients. 
Hereditary neuroblastoma 
Hereditary neuroblastoma, which segregates as an autosomal dominant Mendelian 
trait with incomplete penetrance, is rare (Knudson & Strong 1972; Kushner et al 
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1986; Liu & Thiele 2012). Patients with familial neuroblastoma often have multiple 
primary tumours and are characterized by an earlier median age at diagnosis. Similar 
to sporadic NB patients, hereditary cases also show striking heterogeneity in the 
type of tumours that arise. Missense or nonsense germline mutations in PHOX2B, a 
homeobox gene that is a master regulator of normal autonomic nervous system 
development, explain a small subset of hereditary neuroblastoma, as well as other 
disorders of neural crest-derived tissues (Bourdeaut et al 2005; Krona et al 2008; 
Mosse et al 2004; Trochet et al 2004). However, activating mutations in the tyrosine 
kinase domain of anaplastic lymphoma kinase gene (ALK) located on the short arm 
of chromosome 2 seem to explain the majority of hereditary neuroblastomas as well 
as sporadically occurring cases particularly in high stage tumours. (Janoueix-Lerosey 
et al 2008; Mosse et al 2008). 
 
Figure  5.  Pedigrees representing four different NB families. The panels show the family members ALK status, and if 
they have been diagnosed with NB (filled symbols). Squares indicate male family members and circles females. A diagonal 
line marks a diseased individual. Symbols with a filled dot inside represent ALK mutation carriers, free of disease. A 
family member where ALK analysis was not done is marked with ND (unpublished data). 
Prognostic factors 
The likelihood of cure depends on several prognostic factors, including stage of 
disease, age at diagnosis, histological features, and several genetic and biological 
markers. Children less than one year of age generally have a much better prognosis 
than children diagnosed above this age, with equivalent stages (Breslow & McCann 
1971). 
Expression of neurotrophin receptors 
The interaction between neurotrophic factors and tyrosine kinase receptors has an 
essential role in nerve cells development as well as neuroblastoma behaviour. TrkA 
expressing neuroblastomas have favourable prognosis as a result of mediating 
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apoptosis or differentiation (Kogner et al 1993; Nakagawara et al 1992; Ryden et al 
1996; Suzuki et al 1993). TrkC is also involved in low stage neuroblastoma in 
absence of MYCN amplification (Ryden et al 1996; Yamashiro et al 1996). 
However, expression of full length TrkB is correlated with MYCN amplification 
and aggressive tumours (Nakagawara et al 1994). A truncated form of TrkB is 
mainly found in low stage tumours. 
Ploidy 
The overall copy number or ploidy of neuroblastoma tumours has been found to 
be of prognostic importance (Cohn et al 2009). A hyperploid or near-triploid 
karyotype is representative of favourable NB whereas those with near-diploid or 
near-tetraploid DNA content show metastatic behaviour and poor prognosis 
(Kaneko et al 1987; Ladenstein et al 2001). It assumed that near-triploid cases have 
a fundamental defect in mitosis leading to gains and losses of whole chromosomes, 
or numerical aberration. Near-diploid or near-tetraploid karyotypes have a 
fundamental defect in genomic stability leading to chromosomal rearrangements 
such as unbalanced translocations, or segmental aberrations (Kaneko et al 1987). 
Tumour histology 
To classify NBs for prognostic use according to their histological features, the 
Shimada histopathologic grading system was devised in 1984. It is an age-linked 
classification system that divides the tumours into favourable and unfavourable 
histology groups depending on the degree of neuroblast differentiation, schwannian 
stroma content, and mitosis-karyorrhexis index. A high mitosis-karyorrhexis index 
(MKI) in stroma poor tumours is an indicator of poor prognosis in Shimada 
system. 
Risk stratification 
The International Neuroblastoma Staging System (INSS) was developed in 1986 
(and revised in 1993) to facilitate the comparison of clinical trials worldwide by 
taking into account the age at diagnosis, the spread of disease, and the respectability 
of the tumour, grading NBs from stage 1 to 4, with stage 4 being the most 
aggressive tumours, see Table 1 (Brodeur et al 1993; Brodeur et al 1988). 
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Stage Definition 
1 Localized tumour with complete gross excision, with or without microscopic residual disease; representative 
ipsilateral lymph nodes negative for tumour microscopically 
2A Localized tumour with incomplete gross excision; representative ipsilateral lymph nodes negative for tumour 
microscopically 
2B Localized tumour with or without complete gross excision, with ipsilateral lymph nodes positive for tumour; 
enlarged contralateral lymph nodes must be negative microscopically 
3 Unresectable unilateral tumour infiltrating across the midline, with or without regional lymph node 
involvement; localized unilateral tumour with contralateral regional lymph node involvement; or midline 
tumour with bilateral extension by infiltration (unresectable) or lymph node involvement 
4 Any primary tumour with dissemination to distant lymph nodes, bone, bone marrow, liver, and other organs 
(except as defined for stage 4S) 
4S Localized primary tumour (as defined as stage 1, 2A, or 2B), in patient <1 year, with dissemination limited 
to skin, liver, or bone marrow (marrow involvement should be minimal with malignant cells <10% of total 
nucleated cells) 
Table  1 .  International Neuroblastoma Staging System. Adopted from (Brodeur et al 1993) 
The INSS has been widely used for the last 20 years for the treatment stratification 
of neuroblastoma tumours. However, since the INSS relies on excision of the 
primary tumour to assign patients to stage 1 and 2, it is not suitable as a 
pretreatment staging system and risk assessment. As a consequence, the 
International Neuroblastoma Risk Group Staging System (INRGSS) has recently 
been established (Monclair et al 2009). It is based on tumour imaging rather than 
the extent of surgical resection, Table 2 & 3. The International Neuroblastoma Risk 
Group (INRG) classification system includes INRGSS, age, histology, and grade of 
tumour differentiation, MYCN status, 11q deletion status, and tumour cell ploidy to 
classify NB tumours. 
Stage Description 
L1 Localized tumour not involving vital structures as defined by the list of image-defined risk factors and 
confined to one body compartment 
L2 Locoregional tumour with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone 
marrow (< 10%) 
Table  2 .  International Neuroblastoma Risk Group (INRG) Staging System. For image-defined risk 
factors see (Monclair et al 2009) 		
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INRG 
stage 
Age 
(months) 
Histologic 
category 
Grade of tumor 
differentiation 
MYCN 11q- 
del 
Ploidy Pretreatment  
Risk Group 
L1/L2 
 
GN maturing; 
GNB intermixed    
A Very low 
L1  Any, except GN 
maturing or 
GNB intermixed 
 NA   B Very low 
 
Amp 
  
K High 
L2 <18 Any, except GN 
maturing or 
GNB 
 
NA 
No  D Low 
 Yes  G Intermediate 
   Differentiating NA No  E Low 
 
≥18 GNB nodular; 
Neuroblastoma   Yes   
   
Poorly differentiated 
or undifferentiated NA   
H Intermediate 
    Amp   N High 
M <18 
  
NA 
 
Hyper-
diploid F Low 
 <12   NA  Diploid I Intermediate 
 12 to <18   NA  Diploid J Intermediate 
 <18   Amp   O High 
 ≥18      P High 
MS    NA No  C Very low  <18   Yes  Q High 
    Amp   R High 
Table  3 .  INRG pretreatment risk classification. Adopted from (Cohn et al 2009; Monclair et al 2009) 
GN = ganglioneuroma; GBN = ganglioneuroblastoma; Amp = amplified; NA = not amplified 
Chromosomal abnormalities 
1p deletion 
Deletion of the short arm of chromosome 1 (1p36.3), first reported by (Brodeur et 
al 1977), occurs in 25-35% of all NB (Bauer et al 2001; Caren et al 2008b; Maris et 
al 2001; Martinsson et al 1995). This aberration is correlated with MYCN 
amplification and is found in approximately 70% of high-risk NBs (Maris et al 
2000). The deletion is mainly large and many investigations have been made to 
identify the shortest region of overlap (SRO) of deletions in this region. However, 
the identified regions are not entirely consistent, indicating this region harbours 
several tumour suppressor genes. Whether the loss of heterozygosity (LOH) due to 
deletion of alleles from 1p is an independent indicator of prognosis, remains 
controversial. 
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Chromosome arm 2p: MYCN, ALK, ALKAL2 
Chromosome region 2p24 amplification is detected in 15-30% of NB tumours and 
is associated with advanced disease stage and malignant progression (Brodeur et al 
1984; Caren et al 2008b; Schwab et al 1983). 
The size of amplified DNA encompassing MYCN proto-oncogene can range from 
100 Kb to more than 1 Mb which raises the possibility that additional target genes 
may be co-amplified. However, MYCN (>>100 copies per cell) has emerged as the 
only gene consistently present when DNA is amplified in neuroblastoma cells. 
Homogenously staining regions (HSRs) and double minutes (DMs) chromatin 
bodies were found as the chromosomal sites of amplified MYCN. DMs are located 
extra-chromosomally, whereas HSRs are located at different chromosomes and 
usually not at the resident site. MYCN encodes for a transcription factor that is 
normally expressed during embryonic development. Another important player in 
neuroblastoma, ALK gene is also situated on chromosomal region (2p23.2), often 
present in 2p gain region found in primary NB. Moreover, the ALK gene is 
identified to be mutated or amplified in a majority of familial cases and is also 
affected in sporadic NB (Caren et al 2008a; Chen et al 2008; Janoueix-Lerosey et al 
2008; Mosse et al 2008). Activating point mutation in tyrosin kinase domain of 
ALK is found in 6-12% of sporadic NB cases and ALK gene amplification, 
frequently cooccurring in the MYCN amplicon, in 3-5%. Furthermore, the recently 
described ALK ligand ALKAL2, can also be found within this 30Mb distal portion 
of chromosome 2p and may play a role in wildtype ALK activation, see Figure 6 
(Guan et al 2015; Reshetnyak et al 2015). 
 
 
Figure  6 .  ALKAL2, ALK and MYCN on 2p. Schematic overview of human chromosome 2 showing 
localization of ALK, MYCN and ALKAL2 in the 2p23-pter region. ALK is located at 2p23.2, 
MYCN at 2p24.3 and ALKAL2 more distally at 2p25.3. 
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11q loss 
Deletion of the long arm of chromosome 11 (11q23) is found in 20-45% of NB 
tumours (Attiyeh et al 2005; Caren et al 2008b; Srivatsan et al 1993). It is inversely 
correlated with MYCN amplification and is a good predictor of aggressive tumours 
that lack MYCN amplification (Guo et al 1999). The high frequency of 
chromosomal breaks in the unfavorable 11q deletion group of tumours is 
suggestive of a chromosomal instability phenotype gene located in 11q and 
involved in DNA repair system. 
 
Figure  7 .  Rare case of a constitutional deletion involving the long arm of chromosome 11. The multi-
coloured line shows the total copy number for the different chromosome regions and the red and green line show 
the strongest and weakest allele intensity respectively. We observed the identical 11q del (81.5-102.9 Mb) in 
tumour to that found in constitutional DNA and additionally del 1p (pter-12.1 Mb); del 4p (4.1-33.2 
Mb); dup 7q (76.8 Mb-qter); dup 17 alterations have been observed (indicated by arrows). del, deletion; dup, 
duplication. Adopted from (Passariello et al 2013) 
17q gain 
The gain of parts of the long arm of chromosome 17 (17q25) has been detected in 
about 50% of NB tumours and known as the most frequent genetic abnormality of 
tumours (Abel et al 1999; Caren et al 2008b; Cohn et al 2009; Gilbert et al 1984). 
Gain of 17q always involves the terminal part of 17q. It is hypothesized that the 
gain of genomic material at terminal of 17q can possibly result in a growth 
advantage for tumour cells (Schleiermacher et al 2004). Unbalanced t(1;17) 
translocation resulting in 1p deletion and 17q gain also occurs frequently (Savelyeva 
et al 1994). 
 
 
INTRODUCTION 25	
Other chromosomal aberrations 
Other regions deleted in neuroblastoma include allelic loss for 14q (14q23-32), and 
3p (3p22), which are present in 20% and 15% of NB respectively (Hallstensson et 
al 1997; Srivatsan et al 1993; Suzuki et al 1989). Similar to 11q, 14q deletion group 
also show an inverse correlation with MYCN amplification. However, LOH for 14q 
was evident in all clinical risk groups, suggesting that this rearrangement may be a 
universal feature of neuroblastoma tumour development (Thompson et al 2001). 
ALK (anaplastic lymphoma kinase) 
In addition to major chromosomal rearrangements, there are recurrent genetic 
alterations in the ALK gene in NB. ALK is a receptor tyrosine kinase (RTK) 
encoded by the ALK gene located at chromosome 2p23. ALK was first identified in 
1994 as part of a fusion partner of NPM (nucleophosmin) in the t(2,5)(p23,q35) 
translocation in anaplastic large cell lymphoma (ALCL) (Morris et al 1994; Shiota et 
al 1994). Indeed, ALK fusion proteins due to chromosomal translocations have 
been observed in non-small cell lung cancer and inflammatory myofibroblastic 
tumours but is a rare event in NB (Fransson et al 2015; Kwak et al 2010; Pulford et 
al 2004). Subsequent studies have shown that various fusion genes involving ALK 
together with gene amplification or single nucleotide mutations are common 
mechanisms leading to increased ALK activity (Pulford et al 1997). The full length 
220kDa ALK protein contains three domains, an extracellular ligand binding 
domain, a transmembrane region and an intracellular tyrosine kinase domain 
(TKD). The kinase domain contains a motif with three tyrosine’s YxxYY (Tyr1278, 
Tyr1282, and Tyr1283) that are the major autophosphorylation sites regulating 
ALK activity. In situ hybridization in mouse showed that ALK expression was 
restricted to specific areas in the developing brain with a decrease to barely 
detectable levels after birth (Iwahara et al 1997). Mammalian ALK plays a central 
role in normal developing of the nervous system however when deregulated and 
constantly activated ALK has a great oncogenic potential. 
ALK, MYCN and NB 
In 2000 Lamant et al found full length ALK expression in NB (Lamant et al 2000). 
The ALK gene was further reported to be amplified in NB cell lines and tumours 
(Miyake et al 2002; Osajima-Hakomori et al 2005). In 2008 Mosse et al identified 
ALK as a major familial NB predisposition gene, showing that germ line mutations 
in ALK explain most familial neuroblastoma cases. The Mosse group and also our 
group could furthermore show that sporadic mutations in ALK kinase domain as 
well as ALK amplification were frequent in high-risk tumours (Caren et al 2008a; 
Mosse et al 2008). In addition, ALK can also be activated by rare translocation 
events in NB (Cazes et al 2013; Fransson et al 2015). ALK mutations are present 
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across all neuroblastoma risk groups but has a notable contribution in MYCN-
amplified tumours where the combination of these aberrations result in a particular 
poor outcome (Bresler et al 2014; De Brouwer et al 2010). The stimulated wildtype 
as well as ligand-independent gain-of-function mutants in ALK stimulate initiation 
of transcription of the MYCN which, in turn, directly regulates ALK expression 
(Hasan et al 2013; Schonherr et al 2012). Finally, cotransfection of ALK gain-of-
function mutations and MYCN causes increased transforming capacity leading to 
earlier onset and higher penetrance possibly due to blocking of MYCN-driven 
apoptosis (Berry et al 2012; Schonherr et al 2012; Zhu et al 2012). The ALK-driven 
neuroblastoma mouse model recapitulates syntenic chromosomal aberrations, 
including MYCN amplification, to human neuroblastoma suggesting a synergism 
between MYCN and ALK (Heukamp et al 2012). 
 
	
Figure  8 .  The ALK receptor tyrosine kinase. (A) different mechanisms of ALK signalling activation in 
cancer. The full-length ALK receptor comprising an amino-terminal ECD and an intracellular tyrosine 
kinase domain (in red), connected by a single transmembrane domain (in green). The ALK ECD contains 
two MAM domains (in pink), one LDLa domain (in yellow) and a glycine-rich region (in grey). From right 
to left: activation (gold stars) by point mutations in the context of full-length ALK, activation by the small 
secreted ALKAL2 ligand, activation by intragenic translocation of ALK and subsequent partial loss of 
ECD, activation by fusion partner (in blue) fused to the intracellular tyrosine kinase domain of ALK (in 
red) (not seen in NB), activation by ALK amplification. B) Simple model illustrating a putative positive 
feedback loop in ALKAL2-ALK-MYCN signalling events in neuroblastoma. Adopted from (Hallberg & 
Palmer 2016) 
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ALK as a therapeutic target 
Incidence of relapse is known as the major reason for treatment failure in high-risk 
NB patients (Sung 2012). To date, in neuroblastoma, only limited data is available 
regarding genetic alterations at the time of tumour progression or relapse. An 
accumulation of segmental chromosome alterations at the time of relapse has been 
described (Schleiermacher et al 2010), including tumours of patients who did not 
receive any DNA damaging treatment. The possibility of occurrence of new ALK 
mutations at the time of progression or relapse is of high clinical importance as this 
may lead to new therapeutic possibilities using tyrosine kinase inhibitors 
(Schleiermacher et al 2014). Moreover, The findings on MYCN and ALK 
cooperation in NB suggest that ALK inhibitors also can be used in treatment 
regime of MYCN-amplified NB patients regardless of ALK mutation status – 
obviously a very exciting finding (Schonherr et al 2012; Zhu et al 2012). 
Tyrosine kinase inhibitors 
Due to the importance of activated signal transduction in tumourigenesis a wide 
array of different tyrosine kinase inhibitors has been developed (Druker et al 1996; 
Li & Morris 2008). The ALK mutated variants confer not only differential 
oncogenic activity but also show differential sensitivity to ALK inhibition therapy 
(Bresler et al 2014). The first clinically approved inhibitor of ALK, c-MET and 
ROS1, crizotinib (FDA approved AUG 2011), has shown remarkable clinical 
efficacy in treatment of NSCLC and ALCL harbouring ALK fusions (Christensen 
et al 2007; Mosse et al 2013). However, cellular responses to mutant ALK are 
complex when compared to rearranged ALK, and treatment remains a challenge 
(Bosse & Maris 2016; Hallberg & Palmer 2013). In neuroblastoma, activating 
mutations in the ALK kinase domain are typically refractory to crizotinib treatment, 
highlighting the need for more potent inhibitors. Recently, second generation ALK 
inhibitors have been developed and approved for use in patients with NSCLC. 
Alectinib (CH5424802) (Lu et al 2017) and brigatinib (AP26113)(Katayama et al 
2011) received FDA granted breakthrough therapy designation (BTD) in 2013 and 
2014 respectively. Brigatinib is able to overcome crizotinib-induced 
chemoresistance and effectively induces apoptosis in human neuroblastoma (Siaw 
et al 2016). Ceritinib (LDK378; FDA approved 2014) is also approved for use in 
crizotinib-relapsed NSCLC patients in the US and Europe (Marsilje et al 2013; 
Shaw et al 2014). Lorlatinib (PF-06463922) is a third-generation ALK-TKI 
currently progressing in phase III clinical trials in NSCLC patients (Basit et al 2017; 
Guan et al 2016; Infarinato et al 2016; Janoueix-Lerosey et al 2008). While the 
above-mentioned drugs are all ATP-competitive inhibitors of ALK, they have 
differential binding affinity and therefore differential efficiency in blocking the 
activity of the various ALK resistant mutant forms (Hallberg & Palmer 2013; Mullis 
et al 1986). Thus, a complex picture of ALK inhibition is emerging, with multiple 
distinct resistant subclones arising following primary treatment with particular ALK 
inhibitors. 
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OBJECTIVES 
The overall aim of this thesis was to delineate the culprit genes that may play a 
critical role in development and/or progression of neuroblastoma and also find 
new targets that can be used in patient stratification and precision medicine. 
Paper I 
• To retrospectively determine the frequency by which the 
therapeutically relevant ALK hotspot mutations is discovered at both 
diagnosis and relapse time points 
• To evaluate the role of activating point mutations in the TKD of 
ALK in neuroblastoma progression or relapse and to define its 
potential role in clonal evolution of neuroblastoma 
• To infer if the serial biopsy procedures followed by deep ALK 
sequencing can provide the potential for patient benefit highlighting 
the usefulness of targeted therapy with ALK inhibitors 
Paper II 
• To put forward the hypothesis that the gain of the distal region of 
chromosome 2p, interestingly harbouring three key players in the 
ALK signalling pathway, namely MYCN, ALK and the ALK ligand 
ALKAL2, has important implications for the development of NB. 
This prompted us to investigate this connection in tumours from NB 
patients 
Paper III 
• To explore the variation and frequency of ALK hotspot mutations 
that can go undetected using Sanger-based sequencing chemistry 
• To further define the subclonal heterogeneity of the tumour and their 
potential role in clonal evolution and progression of neuroblastoma 
 
 
OBJECTIVES 29	
Paper IV 
• To characterize the genomic structural variants at basepair resolution, 
and define breakpoint mapping and SRO of deletions and gain, to 
arrive at novel candidate genes in 11q-deleted neuroblastoma tumours 
using genome-wide approach 
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PATIENTS AND METHODS 
TUMOURS, CELL LINES AND CONTROL 
MATERIAL 
In this thesis, we have used primary and secondary NB tumours mainly from 
Swedish patients. In addition, we have used nine NB cell lines and control tissues 
from blood lymphocytes and normal adrenal tissue. 
 
The tumour cell content of the samples was histologically assessed in tumour tissue 
adjacent to that used for DNA extraction. Genomic DNA was extracted from NB 
cell lines or from fresh NB tumour tissue, fresh frozen (-70 °C) or formalin fixed 
paraffin embedded (FFPE) tissue with a DNeasy blood and tissue kit (Qiagen, 
Hilden, Germany), according to the protocol provided by the supplier, or was 
phenol extracted using phase lock gel (Eppendorf AG, Hamburg, Germnay). 
Paper I 
• Tumour DNA from 54 paired diagnostic– relapse NB patients 
Paper II 
• Tumour DNA from 356 NB patients 
• Cell lysate from eight NB cell lines 
Paper III 
• Tumour DNA from 105 NB patients were used 
Paper IV 
• Tumour DNA from 535 NB patients were used 
• Cell lysate from seven NB cell lines (SK-N-BE, Kelly, IMR-32, NB1, 
CLB-BAR, CLB-GE, CLB-GA) 
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METHODS 
Polymerase Chain Reaction (PCR) 
PCR has revolutionized molecular genetics since its introduction in the mid-1980s 
(Mullis et al 1986). PCR is used for multiplying shorter stretches of a defined target 
DNA sequence within a heterogeneous collection of DNA sequences. A PCR run 
consists of a series of cycles comprising three steps, (I) the denaturation of the 
dsDNA template, (II) annealing of primers and (III) DNA synthesis (extension), 
see Figure 9. DNA is elongated from the bound primers in the presence of heat-
stable DNA polymerase and deoxynucleoside triphosphates (dNTPs). The newly 
synthesized DNA strands will act as templates in following cycles. A PCR run can 
be divided into three phases. During the first phase, the exponential phase, the PCR 
product is doubled at every cycle. The next phase is the linear phase in which the 
reaction slows down because the reaction components are consumed and the 
product starts to degrade. In the last phase, the plateau phase, the reaction has 
stopped and no more products are made. In traditional PCR, the products of the 
final phase are often evaluated on agarose gel after staining with Gel Red to 
estimate size, specificity and concentration. This is often called end point detection. 
“Hot start” Taq DNA polymerase for the PCR amplification of DNA has mainly 
been used in this thesis. These types of Taq polymerase utilize different techniques 
to keep the polymerase inactivated until the initial heat activation step, which results 
in more specific, selective PCR amplification. 
 
Figure  9 .  Schematic drawing of PCR amplification 
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Mutation screening methods 
Sanger sequencing 
DNA sequencing is the determination of the precise sequence of nucleotides in a 
template of DNA. Historically, the most common method of sequencing, originally 
developed by Sanger et al in 1977, is called the Sanger method or dideoxy method. 
In this method, fluorescently labelled nucleotides that lack the OH at the 3′ carbon 
atom (dideoxynucleotides, ddNTP) are added to a purified PCR product, together 
with normal deoxynucleotides, DNA polymerase I and one primer. The ddNTPs 
are randomly incorporated and terminates the elongation chain because of the lack 
of 3′ OH for the next nucleotide to be attached to. For this reason, the dideoxy 
method is also called the chain termination method. The sequence reaction will 
result in nucleotide chains of different length, from chains ending directly after the 
forward primer to chains covering the whole amplicon. The nucleotide chains from 
the sequencing reaction are then precipitated and resuspended in a denaturing 
formamide solution to keep them single stranded and separated on an automate 
sequencer where laser excitation of the terminal fluorescent dyes make it possible 
for a software program to present the bases as peaks in an electropherogram. In 
this thesis, Big Dye Terminator ddNTP chemistry from Applied Biosystems was 
used to sequence PCR products from genomic DNA. PCR purification and 
sequencing precipitation were conducted with AMPure magnetic beads and 
CleanSeq magnetic beads, both Agencourt (Agencourt Bioscience Corporation), 
using the Biomek NX pipeting robot (Beckman Coulter). Sequencing was 
performed on 3730 (Life Technologies) in house or at GATC biotech AG, 
European Custom Sequencing Center (Germany). Part of sequencing in paper I to 
III was performed with Sanger. 
 
 
Figure  10. Example of DNA sequencing electrophorogram. Mutation (F1245L) in the ALK gene in a 
NB tumour, upper sequence and reference DNA, bottom sequence. 
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Principles of Massively Parallel Sequencing (MPS) 
Sequencing has been going through a revolution in the last years. Since 2005, 
massively parallel sequencing (MPS), alias next-generation sequencing (NGS), is 
making its way from research laboratories into applied sciences and clinics. This 
technology uses miniaturized and parallelized platforms for sequencing of 1 million 
to 43 billion short readouts (50-400 bases each) per instrument run (Moorthie et al 
2011). Many NGS platforms differ in engineering configurations and sequencing 
chemistry. They share the technical paradigm of massive parallel sequencing via 
spatially separated, clonally amplified DNA templates or single DNA molecules on 
a solid surface either on beads or a flat glass of micro fluidic channels. This design 
is very different from that of Sanger sequencing that is based on electrophoretic 
separation of chain-termination products produced in individual sequencing 
reactions. Fundamental to NGS library construction is the preparation of the 
nucleic acid target, RNA or DNA, into a form that is compatible with the 
sequencing system to be used. For targeted re-sequencing there are mainly two 
technical preparation methods to construct a library of fragments. The first is 
Amplicon-based enrichment assay involving a multiplex PCR reaction with multiple 
primer pairs. Primers include all sequences needed for downstream analysis. The 
second approach is a two-step process, first a sample preparation step of the 
genomic DNA and then a fishing step where the genomic regions of interest are 
captured by hybridization-based technique. The library construction on the second 
approach starts with DNA fragmentation that can be done either by restriction 
enzyme digest, by using transposase or by the Covaris, which is a focused 
ultrasonicator. Then synthetic DNA adapters are covalently added to each fragment 
end by DNA ligase. The adapters in general contain three parts: universal sequences 
specific to each platform, sequence used to amplify the DNA and indexes (also 
called tags or barcodes) used for distinguishing samples when pooling several 
samples together. In MPS, sequencing and detection is done simultaneously and 
include three steps: addition of a nucleotide, detection of the nucleotide incorporate 
and finally a washing step that may include chemistry to remove fluorescent labels 
or blocking groups. 
Bridge amplification and sequencing by synthesis (Illumina) 
This sequencing system was initially developed by Solexa in 2007 and subsequently 
acquired by Illumina. The Illumina flow cell is composed of flat glass with 
covalently attached adapter sequences complementary to the library adapters. A 
diluted solution of the library fragments are immobilized and amplified in situ on 
the flow cell surface by using bridge amplification. The amplification is digital, 
meaning that each DNA molecule is amplified in a cluster that is delimited from 
other DNA molecules. The solid-phase amplification creates up to 1,000 identical 
copies of each single template molecule in close proximity: a “cluster”, whose 
diameter is 1 micron or less. This amplification is necessary to provide sufficient 
signal from each fragment. 
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The fragmented genomic DNA has ligated adapters to both ends of the fragments. 
These fragments will be single-stranded and hybridize randomly to the dense lawn 
of primers existing on the inside surface of the flow cell channels. These primers 
are strand complementary to the adaptor sequences (T5 & T7) and by adding 
unlabelled nucleotides and enzyme the extension initiates. The double stranded 
molecule is denatured and the original template is washed away. Denaturation 
leaves single-stranded templates anchored to the substrate. Then the single strand 
folds over and the adapter region hybridizes to second type of primer on the flow 
cell. The enzyme incorporates nucleotides to build double-stranded bridges on the 
solid-phase substrate. This bridge is denatured resulting in two single stranded 
copies of the molecule that are tethered to the flow cell. The process is then 
repeated over and over and occurs simultaneously for a millions of cluster resulting 
in clonal amplification of all fragments. After bridge amplification the reverse 
strands are cleaved and washed off leaving only the forward strands. The 3' ends are 
blocked to prevent unwanted priming. Sequencing begins with the extension of the 
first sequencing primer to produce the first read. Within each cycle four labeled 
reversible terminators nucleotides compete for addition to the growing chain, only 
one is incorporated based on the sequence of the template. After the addition of 
each nucleotide the clusters are excited by a light source and a characteristic 
fluorescent signal is emitted and captured from each cluster. This process is called 
sequencing by synthesis. The number of the cycles determines the length of the 
reads. The emission wavelengths along with the signal intensity determine the base 
call. For a given cluster all identical strands are read simultaneously. Hundreds of 
millions clusters are sequenced in a massively parallel process. After the completion 
of the first read, the read product is washed away. In this step, the index 1 primer is 
introduced and hybridizes to the template. The read is generated similar to the first 
read. After the completion of the index read, the read product is washed off and the 
3' end of the template is deprotected. The template now bends over and binds the 
second primer on the flow cell. Index 2 is read in the same manner as index one. 
Index 2 read product is washed off at the completion of the step. Polymerase 
extends the second flow cells primer forming a double stranded bridge. This double 
stranded DNA is then linearized and the 3' end is blocked. The original forward 
strand is cleaved off and washes away leaving the reverse strand. Read two begins 
with the introduction of read 2 sequencing primer. As with read one the sequencing 
steps are repeated until the desired read length is achieved. The read-two product is 
washed away. This entire process generates millions of reads representing all the 
fragments. Sequences from pooled sample library are separated based on the unique 
indexes introduced during sample preparation. 
 
For each sample, reads with similar stretches of base-calls are locally clustered. 
Forward and reverse reads are paired creating contiguous sequences that will be 
aligned back to the references genome for variant identification. The pair-end 
information is used to resolve ambiguous alignment. However, Illumina has its own 
systematic base calling biases. Most importantly, different tiles of the sequencing 
plate tend to produce reads of different quality (Dolan & Denver 2008); the 3′ ends 
of sequences tend to have higher sequencing error rates compared to the 5′ ends 
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(Schroder et al 2010), and increased single-base errors have been observed in 
association with GGC motifs (Nakamura et al 2011). Another source of noise is 
dephasing where the different copies of a DNA fragment within a cluster get out of 
synch. If the deblocking doesn't occur on a particular strand, then that strand won't 
incorporate the next nucleotide. But it might be deblocked in the next round, in 
which case it will be one base behind the rest of the cluster. At this point, the 
imaging of the cluster will result in a mix of bases, so the quality will be low for the 
basecall. The Illumina platform was used for amplicon-based sequencing in paper 
III. 
 
Figure  11.  Bridge amplification. Enhance signalling trough increasing the copy numbers of a single 
fragment. From (Metzker 2010). 
Ion Torrent Personal Genome Machine (PGM™) technology 
Life Technologies expanded their NGS portfolio with the acquisition of Ion 
Torrent and their first system, the Ion Personal Genome Machine (PGM) 
sequencer, in 2010. 
 
During library construction according to Ion Xpress Fragment Library Kit, PCR 
products of relevant genomic regions are end-repaired and Ion-Torrent barcoded 
adapters are ligated at the 5’ and 3’ ends. The fragments generated during the library 
prep are attached to beads and amplified using emulsion PCR (emPCR). Beads 
coated with complementary primers are mixed with a dilute aqueous solution 
containing the fragments to be sequenced along with the necessary PCR reagents. 
This solution is then mixed with oil to form an emulsion of microdroplets. The 
concentration of beads and fragments is kept low enough such that each 
microdroplet contains only one of each (or possibly none, but almost never more 
than one). Clonal amplification of each fragment is then performed within the 
microdroplets. The beads are put into a picotiter plate that holds a single bead in 
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each of several hundred thousand single wells married to ion sensor, which provide 
a fixed location at which each sequencing reaction can be monitored. Following 
amplification the emulsion is ‘broken’ (generally by organic extraction and 
centrifugation) and the amplified beads are enriched in a glycerol gradient, with 
unamplified beads pelleting at the bottom. What really differentiates Ion Torrent’s 
systems is the sequencing technology. It is based on the standard pyrosequencing 
chemistry, a form of ‘sequencing by synthesis’ whereby individual bases are 
introduced one at a time and incorporated by DNA polymerase. However, unlike 
other platforms based on pyrosequencing, rather than measuring light released from 
chemiluminescent reagents, the Ion Torrent system measures the direct release of 
H+ (hydrogen ion) from the reaction. As the sequencer floods the chip with one 
nucleotide after another, any nucleotide added to a DNA template will be detected 
as a voltage change, and the PGM™ System will call the base. Because optics isn’t 
required, they’re able to make relatively inexpensive instruments coupled with 
disposable chips, which essentially act as pH meters. The lack of optics also means 
they don’t have to contend with slow image scans, so the sequencing reactions are 
relatively fast, with 200b reads taking about 2 hours. Finally, the lack of 
fluorescence or chemiluminescence means that the system can use unmodified 
nucleotides, which are cheaper and better tolerated by DNA polymerase. While the 
error rates are generally pretty good (~1%), pyrosequencing chemistry has trouble 
with long homopolymers (stretches of the same base, e.g. AAAAAA). Because the 
chemistry does not pause after each base incorporation, stretches of the same base 
will result in a single, albeit stronger, signal. While short stretches can be 
differentiated, it becomes increasingly difficult with longer stretches. The PGM 
technology has been used in paper I. 
 
 
Figure  12.  Emulsion PCR. From (Metzker 2010). 
HaloPlex™ Target Enrichment System 
Agilent acquired HaloPlex platform in December 2011. HaloPlex™ Target 
Enrichment System enables simple and efficient analysis of genomic regions of 
interest in a large number of samples. Custom designs, for panels containing 
thousands of exons, are easily created with SureDesign. Using a simple workflow, a 
DNA sample is fragmented using restriction enzymes, and denatured. The probe 
library is added and hybridized to the targeted fragments; probes can be designed to 
any target sequences. Each probe is an oligonucleotide designed to hybridize to 
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both ends of a targeted DNA restriction fragment, thereby guiding the targeted 
fragments to form circular DNA molecules. The ends of the probe are 
complementary to the desired fragment sequence and the middle part of the probe 
is composed of a sequencing specific motif that is incorporated during 
circularization. In addition, a sample barcode sequence is incorporated in this step. 
The HaloPlex probes are biotinylated and the targeted fragments can therefore be 
retrieved with magnetic streptavidin beads. The circular molecules are then closed 
by ligation, a very precise reaction that ensures that only perfectly hybridized 
fragments are circularized. Only circular DNA targets are amplified, providing an 
enriched and barcoded amplification product that is ready for sequencing. Part of 
sequencing reactions in paper III is performed with HaloPlex technique. 
 
Figure  13.  Schematic overview of library preparation and capture process according to the HaloPlex technology. From (de 
Kock et al 2016). 
Data processing 
The term coverage (depth) is the average number of time that each nucleotide is 
expected to be sequenced assuming that reads are randomly distributed across the 
target region. The coverage can be calculated by number of reads × read length 
(output) / target size × number of samples included. Uniformity of coverage will be 
influenced by low-complexity sequences, which is characterized by a significant 
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proportion of reads sharing identical start sites. This result in a lot of redundant 
sequence reads which just end up in the trash. 
 
Multiple algorithmic approaches have been developed for analysing the output data 
from NGS but it includes the main steps: base calling, quality control, alignment 
and variants calling. Sequencing platforms typically have integrated base calling 
software. Base quality score, a measurement of uncertainty to each base call from 
image analysis, is typically given in the standard Phred quality score (Phred score 20 
corresponds to 1% error rate in base calling). Checking the quality of generated 
read data is often the first step in a pipeline. Read trimming is often done by 
removing poor quality reads, particularly near the sequencing primer site, and 
toward the end of longer sequence runs. BWA (Burrow-Wheeler transform 
algorithm) is short read aligner that has been used in this thesis for alignment of 
reads to a reference genome, human genome build hg19. A good alignment is 
important for the next step of variation detection. Sequence alignments have to 
produce well-calibrated mapping quality scores to predict the accuracy of an 
observed variant. Sequence alignment map (SAM) format data is output from 
aligners that read FASTQ files and assign the sequences to a position with respect 
to a known reference genome. The binary version of SAM is called BAM and the 
SAM/BAM format, has become the standard format for storing the result of 
alignment step that can be used by downstream tool kits. Visualization of the 
alignment can be done in the Integrative Genomics Viewer (IGV). It is 
recommended to remove or at least mark PCR duplicates, arising during library 
amplification, before proceeding to variant calling step. 
A variant call is a conclusion that there is a nucleotide difference versus reference at 
a given position in an individual genome. It is usually accompanied by an estimate 
of variant frequency and measure of confidence. Genotyping identifies the set of 
alleles present at each locus and this is only done for positions were variants already 
have been called. The accuracy of a variant calling depends on mapping quality, 
read depth and allele balance. Ploidy should be considered for cancer genome 
samples. GATK (Genome Analyzer Tool Kit) is the current best probabilistic 
method producing robust estimates of the probabilities of each of the possible 
genotypes. Variant Call Format (VCF) is a standardized text file format for 
representing SNP, indel, and structural variation calls. Furthermore, genome 
annotation is the process of identifying the locations of genes, coding regions and 
other sites of interest in a DNA with descriptive information about function. Once 
a genome is sequenced, it needs to be annotated to make sense of it. 
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CNV methods 
Single Nucleotide Polymorphism (SNP) array 
Single nucleotide polymorphisms (SNPs), the most common variation at a single 
site in the human genome, refer to genomic positions where two or more bases are 
found in the population. With an estimated frequency of about 10 million SNPs, 
evenly dispersed across the human genome, they represent a suitable target for 
large-scale association studies aiming to find the causing genes for the disease in 
question (International HapMap Project, 2003). The assembly of a large number of 
SNP assay to an array was first described in 2003 (Kennedy et al 2003). Although 
this technique was first used for the purpose of high throughput genotyping, it was 
soon recognized that these arrays could also be used for copy number analysis 
(Bignell et al 2004; Zhao et al 2004). 
In high-density oligonucleotide SNP arrays, hundreds of thousands of probes are 
arrayed on a small chip, allowing for many SNPs to be interrogated simultaneously. 
SNP arrays use short oligonucleotides (~25nt) that are located such that a particular 
SNP is covered (Speicher & Carter 2005). Because SNP alleles only differ in one 
nucleotide and because it is difficult to achieve optimal hybridization conditions for 
all probes on the array, the target DNA has the potential to hybridize to 
mismatched probes. This is addressed somewhat by using several redundant probes 
to interrogate each SNP. Probes are designed to have the SNP site in several 
different locations as well as containing mismatches to the SNP allele. By 
comparing the differential amount of hybridization of the target DNA to each of 
these redundant probes, it is possible to determine specific homozygous and 
heterozygous alleles. Separate probes are synthesized to match each of the possible 
alleles, this enabling genotyping of the SNP by comparing the fluorescent intensity 
between the two sets of probes. In addition to genotyping, the fluorescent intensity 
for each probe also enables the copy number to be inferred from the array (Bignell 
et al 2004; Zhao et al 2004). For SNP arrays a separate intensity measurement is 
present for each of the alleles, thus enabling allele specific copy number to be 
analysed in addition to the total copy number. This feature makes it possible to 
detect both loss of heterozygosity (LOH) and copy number changes simultaneously 
(Sato-Otsubo et al 2012; Speicher & Carter 2005). SNP arrays are performed as 
single channel experiments, with only a single sample hybridized to each array. The 
fluorescent intensities are then compared in silico, either to a set of reference 
samples from healthy individuals or to the matched control sample from the same 
patient. The resulting copy number plot then shows the change in copy number 
relative to the controls used. 
 
In this thesis, the tumours where analysed for copy number changes and LOH 
using either Genechip® Human Mapping 50K, 500K NspI, SNP array 6.0 or 
CytoScan® HD (Affymetrix Inc., Santa Clara, CA). Here the most used array is the 
Mapping 500K from Affymetrix that is comprised of two arrays, each capable of 
genotyping on average 250,000 SNPs. The array that uses the NSP I restriction 
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enzyme (approx. 262,000 SNPs) has been used here, with an average distance 
between SNPs of 11 kb. We also used CytoScan® HD, 750,000 SNP probes and 1.9 
million non-polymorphic probes, with a mean marker distance of 1 SNP per Kbp 
that has highest resolution to accurately detect breakpoints, LOH, regions of 
identical-by-descent, maternal contamination, and low-level mosaicism. The array 
experiments were performed at our lab according to the protocol provided by the 
supplier (Affymetrix, Inc., Santa Clara, CA). Briefly, total genomic DNA (250 ng) 
was digested with the restriction enzyme and ligated to adaptors. After ligation, the 
template was subjected to PCR amplification using a generic primer that recognizes 
the adaptor sequence. PCR conditions have been optimized to preferentially 
amplify fragments in the 200 to 1,100 bp size range. The purified PCR products 
fragmented with DNase I, end labeled with biotin by using the enzyme Terminal 
Deoxynucleotidyl Transferase (TdT) before hybridized to a GeneChip Human 
Mapping array. The hybridized probes were washed using the Affymetrix Fluidics 
Station 450 and marked with streptavidin-phycoerythrin. The arrays were scanned 
using a confocal laser scanner, GeneChip Scanner 3000 (Affymetrix, Inc., Santa 
Clara, CA). To ensure proper detection of LOH regions in the case of tumour 
heterogeneity or containing significant normal cell components, we have used the 
AsCNAR algorithm available in CNAG 3.0, 3.3 and 3.5.1. When calculating the 
allele specific intensities, this algorithm takes advantage of the false heterozygous 
calls that might appear as a result of contaminating normal cells. This makes it a 
reliable method for genome wide detection of LOH and other allelic imbalances 
even in complex tumour materials (Nannya et al 2005; Yamamoto et al 2007). The 
ChAS software 2.1 and 3.1 (Affymetrix) was also used in the analyses. 
 
 
Figure  14.  Results of a NB tumour analyzed with the Affymetrix SNP array, visualized with GCOS 
software. The patient displays 11q deletion genomic profile with several segmental aberrations. Gains (red 
arrows) and losses (blue arrows). wcg, whole chromosome gain 
Data Analysis & software 
GeneChip® operating software (GCOS) and GeneChip® Genotyping Analysis 
Software (GTYPE, Affymetrix) were used for primary data analysis, normalization 
against internal control features on the chip, genotype calling and quality control. 
Subsequent analysis was then performed using Copy Number Analyzer for 
GeneChip (CNAG 3.0, Genome Laboratory, Tokyo University) featuring the 
algorithm for Allele-specific Copy-Number analysis using Anonymous References 
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(AsCNAR) and also ChAS software 2.2 (Affymetrix) was also used. In CNAG, the 
tumour samples were compared in silico to the 6 best-matched control samples 
(lowest standard deviation) available among a set of non-matched healthy 
individuals. This set contained both HapMap samples available from Affymetrix as 
well as our own set of healthy control samples. All cases of chromosomal gain, loss, 
or amplification were scored for both segmental and numerical aberrations, 
including detailed information about the breakpoint positions when applicable. The 
UCSC genome browser, assembly February 2009 http://genome.ucsc.edu/, was 
used to visualize gene regions. 
Cell culture and immunoblotting 
Neuroblastoma cell lines were cultured in RPMI-1640 or DMEM medium 
supplemented with 10% foetal bovine serum (FBS) and 1% penicillin and 
streptomycin at 37°C, 5% CO2, 95% humidity. Cells were harvested in lysis buffer 
(25 mM of Tris-Cl, pH 7.5, 150 mM of NaCl, 1% (v/v) Triton X-100, 1 mM DTT, 
protease inhibitor cocktail tablet (Roche)). Cell lysates were cleared by 
centrifugation at 14,000 rpm for 15 minutes at 4°C, after which the samples were 
boiled in SDS sample buffer, and subsequently were run on SDS-PAGE, followed 
by immunoblotting using ALK (D5F3, Cell Signalling Technology), ALKAL1 
(HPA027368, Atlas Antibodies), DLG2 and Tubulin (#2144, Cell Signalling 
Technology) antibodies. Horseradish-peroxidase HRP conjugated goat anti-mouse 
IgG and goat antirabbit IgG secondary antibodies (1:5000) were from Thermo 
Scientific. 
Statistical methods 
Fisher's exact test 
Fisher's exact test, which is a hypothesis test of small samples that is an alternative 
to the Chi squared test, is used in the analysis of 2x2 association tables. The method 
is used in paper I to compare percentages of base frequencies (allele fractions) 
between data sets, i.e. for a given base between a case and the controls. 
Kaplan-Meier survival analysis 
The probability of surviving a given length of time can be calculated by applying 
Kaplan-Meier method. The survival curve is a series of declining horizontal steps 
(e.g. dead of disease). On the plot, small vertical tick marks indicate individual 
patients whose survival times have been censored (e.g. alive with or without 
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disease). In paper III and IV survival probability rates were calculated using this 
approach. 
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RESULTS AND DISCUSSION 
Paper I 
Many NB patients experience relapse after successful initial treatment. Knowing 
more about the molecular properties of tumours at the time of relapse is a 
prerequisite to benefit from targeted molecular therapy. However, the actual 
frequency of ALK actionable mutations at relapsed neuroblastoma has not been 
studied at the time of this paper. To do this, we analysed ALK Sanger sequencing 
data for 54 paired neuroblastomas profiled either at diagnosis or at disease relapse 
matched with constitutional DNA. ALK mutations were observed in nine of 54 
diagnostic samples. For all nine cases, the same mutation was also detected by 
Sanger sequencing in a sample obtained at the time of relapse. In one case, an ALK 
mutation, detected at diagnosis was present in at relapse in only one of several 
samples. Moreover, the ALK mutation was found in only one of several stroma-
poor nodules having high mitosis-karyorrhexis index (MKI) and not in the other 
nodul or in the stroma-rich component. In 5 additional cases, de novo ALK 
mutations were also detected by Sanger only at the time of relapse. These relapse-
specific mutations were a F1174L mutation (exon 23) in two cases, a F1174S 
mutation (exon 23) in one case, and a Y1278S mutation and R1275Q mutation 
(exon 25) in the other two cases. 
 
Applying IonTorrent PGM technique on these cases, we then sought to determine 
whether the ALK mutation might in fact have gone undetected in the diagnosis 
samples due to a limit in sensitivity of the Sanger technique. We sequenced the 
relevant ALK hotspots in four of five cases with an ALK mutation present only at 
relapse. For the fifth case, no sufficient material was available. In 2 cases with an 
ALK mutation detected in the relapse sample, PGM analysis of diagnosed sample 
showed no evidence of mutated allele presence. Interestingly, in two other cases, 
PGM analysis revealed the base corresponding to a mutated allele in the diagnosis 
sample in a significantly higher frequency than the controls. In one of these two 
cases, an ALK mutated subclone was identified at diagnosis at the frequency of 
0.79%. Strikingly, in another case an ALK mutation distinct from the one observed 
at relapse, but leading to the same AA change, was observed in 8.15% at diagnosis. 
We believe that a mutational switch with an expected identical functional 
consequence has happened relating this case. 
 
Finally, to search for further evidence of clonal selection of ALK mutant cells, two 
established cell lines (CLB-Ma and CLB-Ba), with a previously described F1174L 
mutation observed by Sanger sequencing were compared to the corresponding 
primary sample. For CLB-Ma PGM™ analysis of the primary tumour tissue did not 
reveal any ALK-mutated subclone. However, the cell line has been established from 
 44  RESULTS AND DISCUSSION	
 
the infiltrated bone marrow. Since there was no sample from this bone marrow 
available for PGM analysis, the presence of ALK-mutated subclone in a metastatic 
site cannot be excluded. For CLB-Ba, on the other hand, the PGM analysis of 
invaded bone marrow from which the cell line was directly established showed the 
presence ALK mutation in 6.6% of all reads. This is an evidence for the presence of 
an ALK-mutated subclone in the primary sample which expanded during 
establishment of the cell line contributing to a selective advantage. We have shown 
that the ALK mutational events increase at relapse, likely as a result of clonal 
evolution of mutation-carrying cells during primary treatment. The potential of 
targeted molecular inhibitors justifies repeated tumour sampling as a new standard 
of care. 
 
Our data suggest that neuroblastomas undergo substantial mutational evolution 
during therapy, and that relapsed disease is more likely to be driven by a targetable 
oncogenic pathway, highlighting that it is critical to base treatment decisions on the 
molecular profile of the tumour at the time of treatment. However, it will be 
necessary to conduct prospective clinical trials that match next-generation 
sequencing results to targeted therapeutic intervention to determine if cancer 
genomic profiling improves patient outcomes. 
Paper II 
Segmental chromosome alterations (SCAs) most often involving chromosome 
regions 1p, 1q, 2p, 3p, 4p, 11q and 17q are frequently observed in advanced stages 
of NB. However, frequently detected gene alterations are limited to MYCN 
amplification (20%) and ALK activations (7%). ALK interplay with MYCN in NB 
pathogenesis as ALK mutation or amplification, most commonly affecting one of 
the three hotspot residues in the ALK kinase domain (F1174, R1245 and R1275), 
happens predominantly in MYCN-amplified NB cases. 
 
The human ALK locus, spans 728kb (chr2:29,192,774-29,921,566), as well as 
MYCN locus, spans 4,4kb (chr2:15,940,564-15,947,007), are found at the distal 
portion of 2p, where it is frequently the target of amplification in NB 
(GRCh38/hg38 Assembly). High-level amplifications of ALK co-occurs with 
MYCN amplification in an estimated 2% of NB while focal amplification of ALK 
alone is a rare event (Caren et al 2008a; Mosse et al 2008). Furthermore, the recently 
described ALK ligand ALKAL2, spanning 8,7kb in chr2: chr2:279,558-288,296, can 
also be found within this 30Mb distal portion of chromosome 2p, along with ALK 
and MYCN (Guan et al 2015; Reshetnyak et al 2015). What advantages does 2p 
gain provide in the development of NB? An obvious first candidate is MYCN 
oncogene representing one of the most powerful prognostic markers in NB 
malignancy (Ambros et al 2009). The tumourigenic potential of MNA process is 
most probably a consequence of an increase in gene dose in a range of 40-200 
copies which is a highly demanding process for the cell (Levan et al 1976). An over 
fourfold increase in the MYCN signals number relative to chromosome 2q indicates 
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a MYCN-amplified tumour (Ambros et al 2003). In order for MYCN amplification 
that increases gene expression to contribute to adaptive evolution, the fitness 
advantages of increased gene expression must outweigh any decrease in fitness 
associated with the energetic costs of increased gene expression. This fact argues 
against gain of one single copy – i.e. going from two to three copies, as in the case 
of 2p gain, being sufficient for promoting tumour development/progression. 
 
The recent discovery of the ALK ligands (Guan et al 2015; Reshetnyak et al 2015), 
one being ALKAL2 (FAM150B/AUGα), with a genetic locus in the genomic 
proximity of MYCN and ALK, makes it tempting to speculate that the 2p gain in 
NB tumours is not solely due to the tumour benefitting from an extra copy of 
MYCN but instead from an extra copy of a NB promoting 2p gain cassette 
including three genes i.e. ALKAL2, MYCN and ALK. 
 
In this paper, we analysed a large set of NB tumours (n=356) for presence of 
segmental aberration including amplification and segmental loss or gain. The extent 
of aberrations on 2p was defined and for clarity, we also included ALK mutation 
data where possible. Overall 107 of the 356 NB cases examined exhibited either 
gain or amplification of 2p. The most common gain on 2p contains all three genes 
which lends support for the hypothesis that gain of ALKAL2, MYCN and ALK 
provides an advantage to NB growth. In addition, we observed that ALK mutation 
is almost exclusively present in the MYCN-amplified group. 
 
Since it was of interest to analyse for mutations in the ALK gene in the group of 
NB tumours with rearrangements in 2p we subjected available samples to Sanger 
sequencing for ALK tyrosine kinase domain covering exons 21-25. 8 out of 107 
cases showed ALK amplification. 67 out of 107 patients were negative for ALK 
mutation; 11 out of 107 cases (10.2 %) were positive for ALK mutation detected by 
Sanger method; They were all in either of positions 1174, 1245 or 1275, which are 
the most common positions for ALK mutation in NB tumours. ALK sequencing 
was not performed in 21 patients due to lack of material. None of the cases with 
ALK amplification carried an ALK mutation. High levels of ALK expression, due 
to mutation or amplification, can lead to ligand independent constitutive oncogenic 
activation in cancer cells; however, such findings suggest that ligand dependent 
activation of the wildtype ALK receptor concomitant with MYCN protein 
stabilization may play an important role in NB pathogenesis. The question of 
whether therapeutic options targeting ALK signalling should be considered in 2p 
gain NB remains to be addressed. 
Paper III 
In the following study, we wanted to expand our investigation of the potential 
occurrence of ALK tyrosine kinase domain hotspot mutations that might be 
present at an allele frequency below the detection limit of Sanger sequencing 
technique. Tyrosine kinase inhibitors have become the gold standard therapy in 
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treating ALK positive NBs, making diagnostic high sensitive detection of ALK 
point mutations a necessary step in identifying optimal treatment modalities. 
In a clinically representative series of 105 NB samples, point mutational status of 
the ALK gene within exons 23, 24 and 25 (exons 21-25 in HaloPlex assay) 
containing the F1174, R1245 and R1275 mutation hotspots respectively, were 
sequenced using an amplicon-based deep sequencing assay (5000-30000X). 
 
ALK point mutations were detected in sixteen out of the 105 (15.2%) tumour 
samples while gene amplification was noticed in additional four samples, giving a 
total of ALK mutational events in 20 of 105 neuroblastoma samples (19%). 
 
At the I1171 locus (chr2:29445213), an ALK variant was detected in one case with 
the frequency of mutated allele as low as 2.7%. This was the lowest variant 
frequency level detected by deep-targeted sequencing in our cohort. At the F1174 
hotspot (chr2:29443695-29443697), alterations were observed in eleven cases: seven 
cases harboured a mutation leading to the amino acid change F1174L, two cases 
with F1174I, one each of the F1174C, and F1174S substitutions, with the MAF 
ranging from 14% to 60%. Interestingly the patient harbouring F1174S mutation 
with 58% frequency, in parallel contained a small subclone of F1174I mutation with 
8% frequency of the mutated allele. At the F1245 hotspot (chr2:29436858-
29436860), alterations were detected in 3 tumours: two samples showed a F1245I 
mutation while the third case carried the F1245C mutation, with frequencies of 
14%, 51% and 52%, respectively. At the L1240 locus (chr2:29436875) a L1240V 
substitution were detected in one patient with a MAF at 57%. Altogether ALK 
mutations with a variant allele frequency less than 20% were detected in six 
tumours while ten other cases showed ALK mutations with higher variant allele 
frequency (between 20-60%). No additional variants outside previously reported 
mutational sites were observed in the targeted regions in our cohort. 
 
Our results fail to reveal a distinct mutational spectrum in relation to NB different 
genomic subtypes (numerical only, other segmental, 17q gained or MYCN-
amplified). However, no ALK mutations were detected in any of the tumours 
carrying segmental 11q-deletion (n=27). No statistically difference in overall 
survival was seen when comparing ALK-positive (including ALK amplified) 
neuroblastoma with neuroblastoma with wildtype ALK. 
 
All four cases with ALK gene amplification also had co-amplification of MYCN 
and no ALK mutation was detected in any of these samples. Focal low copy 
number gain for ALK was also detected in one MYCN-amplified patient who also 
had a chromothripsis pattern for chromosome 2. The partial 2p gains 
encompassing the ALK locus were present in only 4 of 16 mutated tumours 
indicating that 2p gain is not a common mechanism for increasing mutated ALK 
copy number. This is while 2p gains are present in as much as 19.3% of all 
neuroblastomas with segmental imbalances (Caren et al 2008a). Interestingly, all 
patients (n=4) with partial 2p gain that also carries an ALK mutation is dead of 
disease. We observed that the majority of MYCN-amplified tumours (4 of 6) 
contained subclonal (<20% variant allele fraction) ALK aberrations while in 
 
 
RESULTS AND DISCUSSION 47	
MYCN-nonamplified tumours the majority of ALK mutations (8 of 10) were 
clonal. This implies that MYCN-nonamplified tumours are dependent on the 
presence of this constitutive active kinase in a higher percentage of the cell 
population. 
All ALK mutated samples were also tested by Sanger sequencing which confirmed 
all ALK mutations occurring with a mutated allele fraction above 15% leaving four 
samples with a mutated allele fraction below 15% undetected by Sanger sequencing 
in our hands. Three of neuroblastoma associated mutations, F1174L/I/S, I1171T, 
and F1245C, observed in our dataset are known to confer strong gain of function 
effect to ALK in vivo assays, whereas the F1174C, F1245I and L1240V function as 
oncogenic drivers in the progression of NB tumours are not yet characterized 
(Hallberg & Palmer 2013). 
 
The post-treatment follow-up examination should include the ALK mutational 
status, since the elevated frequency of mutated allele values herald the appearance 
of a recurrence (Schleiermacher et al 2014). During this study we have observed 
that prognosis value of ALK as a single factor in primary NB tumours can be 
misleading because of the extremely heterogeneous prognosis based on the 
neuroblastoma patient's age, stage, and biology. These findings are of clinical 
importance given the potential role of ALK mutations in clonal evolution and 
relapse. The efficacy of ALK-inhibitors on cells harbouring ALK mutations at 
subclonal level remains to be determined. 
Paper IV 
Deletion of the long arm of chromosome 11 is one of the most frequent events 
that occur during the development of aggressive neuroblastoma. Clinically, 11q 
deletion is associated with higher disease stage and decreased survival probability. 
Chromosome 11, although average in size, is one of the most gene-rich 
chromosomes, an average gene density of 11.6 genes per megabase, including 1,524 
protein-coding genes. Despite extensive efforts to identify the recurrently involved 
genes, and to understand the molecular mechanisms of 11q deletion, definitive 
answers are still unclear. In this article, it is our intent to provide a deeper 
understanding of 11q deletion role in the development and/or progression of NB. 
 
To do this, we performed a comprehensive genome-wide analysis of DNA copy 
number in 535 NB tumours using 250 k and/or Cytoscan HD gene chip arrays 
from Affymetrix. 120/535 patients (22%) had deletion of the long arm of 
chromosome 11. Tumours with 11q deletion contained significantly more 
chromosomes with breaks compared to MYCN-amplified tumours and significantly 
more chromosomal breaks overall. This subgroup contains many additional 
recurring large-scale chromosome imbalances including loss of 4p, 9p, 14q, and 
gain of 1q, 7q, 2p, and 11p. While 11q deletion is more frequently detected than 
MNA (35-45% vs. 20-25%, respectively), both alterations are almost mutually 
exclusive, only 26 cases (4,7%) had both MYCN amplification and 11q deletion. 
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Two regions of the chromosome 11q SRO of deletions were identified; It is 
possible that the elusive 11q tumour suppressor gene could actually be more than 
one, and located in two separate regions, one larger and more proximal (85,3–103 
Mb), associated with non MYCN-amplified tumours, and one smaller and more 
distal (111–118/qter), associated with amplified tumours. Thus, we suggest that 
different sets of 11q-deleted genes are important for the biological behaviour of the 
MYCN-amplified and the non-MYCN amplified cases (see Table 4 for a summary). 
 
Chromosome 11 rearrangements Frequency  SRO 
Entire chr 11 loss 18% (n=98/535)  
Partial 11q loss 22% (n=120) for MNA 111.0 -118.0 
for MNA-neg 85.3 -103 
 
Interstitial 11q loss 1,8% (n=10) 84.8-87.0  
Homozygous 11q losses          (n=0)  
Gain/amp chr 11 10%  (n=53) 68.5-70.7 
Constitutional 11q loss          (n=1) 81.5–102.9 
Table  4 .  Summary of findings in the study. MNA, MYCN amplification; SRO, shortest region of 
overlap 
We observed that the 11q deletion rearrangements most often found to interfere 
with DLG2 normal gene function by directly disrupting the gene structure (chr11: 
83,455,012-84,923,589) or the breakpoint can occur approximately 50 kb upstream 
of the intact loci. Moreover, one of the 11-deleted samples showed a small 
interstitial 11q deletion harbouring 16 genes. Among these genes there are 2 
candidates, DLG2 and CREBZF, which show a significant lower expression level in 
unfavourable neuroblastoma compared to favourable in R2 database. In all 
different subsets of NB patients, there was a very strong correlation between DLG2 
low expression and worse outcome of disease, indicating a possible role for DLG2 
as a tumour suppressor gene (R2: microarray analysis and visualization platform 
(http://r2.amc.nl)). According to this along with the evidence coming from the 
tumors copy number variations (CNVs) screening, DLG2 turns out to be the most 
proximal appropriate driver gene as the locus position overlaps the shortest region 
of overlap (SRO) for the deletion and it harbours recurrent somatic structural 
variations within the gene body. Disruption of the DLG2 gene can be a target of 
LOH observed in neuroblastomas, which have lost the long arm from one of its 
chromosome 11. However, we could not find any supplementary genetic lesion in 
addition to the primary copy number variant observed in DLG2 reflecting gene 
dosage sensitivity mechanisms. 
 
To further investigate DLG2 as a tumour suppressor gene in neuroblastoma we 
investigated the expression of DLG2 protein in a range of neuroblastoma cell lines: 
CLB-BAR, CLB-GA, Kelly, IMR32, NB1, SKN-BE and CLB-GE. DLG protein 
levels were undetectable in most neuroblastoma cell lines tested, with the exception 
 
 
RESULTS AND DISCUSSION 49	
of the CLB-GE cell line. We could see no significant difference in the DLG2 
expression level between 11q-deleted and 11q-normal NB cells. 
To examine DLG further, we employed the Drosophila system, where Dlg has 
been shown to function as a growth suppressor. Examination of the larval 
neuromuscular junctions revealed a co-localization of Dlg protein with the 
Drosophila Alk receptor homologue. However, inhibition of Alk signalling did not 
affect Dlg expression or localization. 
 
In 53 out of 120 11q-deleted tumours, we could localize a large genomic gain or 
amplification at 11q13 proximal to the 11q-deleted region while others had an intact 
copy number change through the chromosome 11 until the appearance of terminal 
deletion. The consensus region spans approximately 2 Mb (68.5-70.7Mb) and 
contains Cyclin D1 (CCND1) candidate gene that is important for transition 
through the G1 checkpoint of the cell cycle.  
 
We found no substantial difference in MYCN copy number between samples of 
neuroblastoma obtained from primary and metastatic sites from the same patient. 
In contrast, there can be differences in 11q status between diagnosis vs. metastasis 
samples obtained from the same NB patient. Here we observed three MYCN-
amplified cases with intact chromosome 11 at the time of diagnosis, which had 
evolved 11q deletion after treatment procedure. Therefore, 11q segmental 
chromosomal loss cannot be the primary event during NB development. This 
particular observation underscores the opinion that 11q alterations are probably late 
and mostly secondary events in tumour evolution. 
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CONCLUSION 
The observation of new ALK mutations at relapse suggests that the frequency of 
ALK mutations maybe higher at relapse than at diagnosis. 
 
Subclones harbouring ALK mutations may contribute to tumour evolution and 
relapse. This has major clinical implications. 
 
Intratumour heterogeneity of ALK may hinder therapeutic strategies that depend 
on results from single tumour biopsy sample or single time point. 
 
NB tumours with 2p gain benefits from an extra copy of a NB promoting 2p gain 
cassette including three genes i.e. ALKAL2, MYCN and ALK. 
 
There were no significant survival differences observed in tumours with or without 
ALK mutations or amplifications. 
 
Prognosis value of ALK as a single factor in primary NB tumours can be 
misleading because of the extremely heterogeneous prognosis based on the 
neuroblastoma patient's age, stage, and biology. 
 
In our hands, no ALK mutation was detected in any of NB tumours carrying 
segmental 11q-deletion. 
 
11q-deleted tumours with MYCN amplification had generally smaller 11q deletions 
than 11q-deleted tumours without MYCN amplification and the deleted region 
located more distally in this group. 
 
11q-deleted NB tumours present not only loss of a putative tumour suppressor 
gene, DLG2, but also frequent gain of an oncogenic driver, CCND1. These 
findings have a potential clinical implication when it comes to increasing the 
accuracy of grouping and subgrouping patients with NB. 
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FUTURE PERSPECTIVE 
Growing evidence indicates that cancers contain many subclonal mutations, defined 
as mutations that are present in a few cells. These subclones are derived from the 
founding clone, and are defined by the additional mutations they carry, which are 
not present in the bulk population. The full portrait of cancer cell diversity over 
different sites and on different time points reveals a staggering complex contexture. 
There is intratumour diversity on the genetic, epigenetic, transcriptome and protein 
levels. We need to assess the degree to which genotypic and phenotypic 
heterogeneity correspond within a tumour. One important question is if subclonal 
mutations really have an effect on tumour cell phenotype? It is yet unclear whether 
such changes are merely consequences of increased proliferation under stress or 
have an important role in tumour growth through clonal collaboration? 
Intratumour diversity as general may be a clinically useful parameter for risk 
assessment. However, it is not yet clear if advances in tracking the genetics of 
individual cancer cells precisely will be able to introduce clinically actionable targets 
and reduce the incidence of invasive cancers. The efficacy of targeted therapy 
approaches against a subclonal driver mutation present in a subset of cells within a 
tumour must be further investigated. 
 
Evolutionary studies of cancer by analysing tumour types with a moderate level of 
genetic complexity is essential in order to obtain clearer information on basic 
evolutionary patterns. This allows us to plot subclonal hierarchies and to follow 
whether the specific architecture is preserved during dissemination to metastatic 
sites and up to the point of treatment resistant. Moreover, analyses of recurrent 
patterns of coexisting subclones will allow us to form hypotheses for subclonal 
collaborations. However, studying evolution from single time point is hard! 
Recently, liquid biopsies based on circulating cell-free DNA (cfDNA) analysis are 
described as surrogate samples for molecular analysis. The non-invasive nature of 
cfDNA sampling enables sequential analysis for tumour genetic profiling which 
shed light on the spatial and temporal genomic heterogeneity of neuroblastoma. 
The remaining challenge is to transform the expected dynamics of gene frequency 
changes into a more mechanistic theory of evolutionary genomics. 
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